Current and future applications of the anti-IgE antibody omalizumab
Cristoforo Incorvaia1, Marina Mauro2, Gian Galeazzo Riario-Sforza1,Franco Frati3, Francesco Tarantini4, Maurizio Caserini41Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant’Anna Hospital, Como, Italy; 3University Department of Obstetric, Gynaecologic and...
Saved in:
Main Authors: | Cristoforo Incorvaia, Marina Mauro, Gian Galeazzo Riario-Sforza, Franco Frati, Francesco Tarantini, Maurizio Caserini |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/b6d7e8c42c774daebd5b7d44aa092c41 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
by: Luke F. Pennington, et al.
Published: (2016) -
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
by: Pascal Gasser, et al.
Published: (2020) -
Two decades with omalizumab: what we still have to learn
by: Incorvaia C, et al.
Published: (2018) -
Development and characterization of a unique anti‐IgE mouse monoclonal antibody cross‐reactive between human and canine IgE
by: Akiko Kumagai, et al.
Published: (2021) -
Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
by: J. M. Orengo, et al.
Published: (2018)